Melanoma epidemiology, biology and prognosis  by Ali, Z. et al.
Melanoma epidemiology, biology and prognosis1359-6349/$ - see front matter Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
http://dx.doi.org/10.1016/j.ejcsup.2013.07.012
* Corresponding author: Tel.: +44 207 352 8171.
E-mail address: james.larkin@rmh.nhs.uk (J. Larkin).Z. Ali, N. Yousaf, J. Larkin *
Royal Marsden Hospital, London, UK1. Introduction
Melanoma is a cancer arising from the malignant transforma-
tion of melanocytes. These pigment-producing cells derive
embryologically from pluripotent neural crest stem cells. Dur-
ing foetal development they not only predominantly migrate
to and differentiate within the epidermis, but also to other ex-
tra-cutaneous pigment-containing sites such as the eyes,
meninges, oesophagus and mucous membranes. Three sub-
types of melanoma can therefore be characterised: cutaneous
melanoma (the most common) arising from melanocytes in
the epidermis, mucosal melanoma from melanocytes resid-
ing in the mucous membranes and uveal melanoma from
melanocytes residing in the ocular stroma. In this chapter
we will consider each of these melanoma subtypes in turn,




Cutaneous melanoma is by far the most common melanoma
subtype, accounting for in excess of 90% of cases of mela-
noma [1]. Melanoma is reported as the 19th most common
cancer worldwide, with estimated age-standardised inci-
dence rates of 2.8–3.1 per 100,000 [2]. There is considerable
variation in incidence between countries, with the highest
rates reported in Australia (37 per 100,000) and the lowest in
South-Central Asia (0.2 per 100,000). This trend is attributed
to variations in racial skin phenotype, as well as differences
in sun exposure around the world; in the United States (US),
for example, 98.2% of cases are reported amongst white-
skinned individuals [1].
Europe lags behind Australia and the United States in
terms of incidence rates, but the statistics demonstrate that
even within Europe incidence rates vary widely [3]; Switzer-
land has the highest rates (19.2 cases per 100,000) with Greece
recording the lowest (2.2 cases per 100,000). There is also evi-
dence of clear North–South and East–West incidence gradi-ents across the continent. The reason for such marked
intra-continental variation in incidence is unclear and may
well be associated with differences in affluence and conse-
quent recreational sun exposure. However, it is also likely to
be (at least in part) related to discrepancies in cancer registra-
tion [4] between different countries, in particular in Eastern
Europe.
Unfortunately the incidence of cutaneous melanoma
around the world has been rising annually [5–7], at a rate fas-
ter than that of any other malignancy. This is of particular
concern given the unusual age demographics of the disease.
Unlike other solid malignancies, where the majority of cases
are diagnosed at over the age of 65, melanoma affects a high-
er proportion of younger patients, with a median age of diag-
nosis of 57 years. Age-specific incidence rates increase
steadily from the third to the ninth decades of life. There is
a female preponderance in younger age groups (4:10 in 20–
24-year-olds) which changes to a male preponderance (16:10
in >85-year-olds) after a sharp increase in incidence amongst
males from the age of 55 onwards [8]. Estimates from the Uni-
ted States [9] quote a lifetime risk of melanoma as 1 in 56 for
women and 1 in 37 for men, with UK estimates at 1 in 60 for
women and 1 in 61 for men [10], further highlighting global
differences. Australia/New Zealand has the highest global
melanoma mortality rate (3.5/100,000) followed by North
America (1.7/100,000) and then Europe (1.5/100,000) [3]. Over-
all, mortality rates are higher amongst men than women
[11], perhaps because of the later presentation of disease.
Several risk factors thought to be significant in the devel-
opment of cutaneous melanoma have been identified by epi-
demiological studies. These can be grouped into
environmental factors and genetic factors, but there is clearly
interplay between both genetics and the environment to ac-
count for such a wide variation in disease demographics.
Pigmentation has an indisputable and significant influ-
ence on skin susceptibility to malignant change. The melano-
cortin 1 receptor (MC1R) is a melanocyte cell-surface receptor
that induces pigment production (via the signalling cascade
recruitment of MITF) following activation by its ligand, al-
pha-melanocyte-stimulating hormone (MSH) [12]. There are
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numerous skin-colour phenotypes seen in humans; variants
such as the red hair, fair-skinned phenotype express low pig-
mentation, with a consequent increased sensitivity to ultravi-
olet (UV) light and associated increased melanoma risk [13].
As implied above, the main environmental factor impli-
cated in the development of cutaneous melanoma is UV radia-
tion. The incidence of melanoma is highest in equatorial
regions, and decreases with increasing distance from the equa-
tor [14,15]. This directly corresponds with UV light exposure,
particularly UV-B levels [16–18], and occurs regardless of skin
type. Although a direct causal link has not been established,
epidemiological studies [17,19] have repeatedly demonstrated
an association between the pattern and timing of sun exposure
and melanoma. The majority of cutaneous melanomas arise
on sporadically (rather than chronically) sun-exposed skin, in
sites and individuals more prone to sunburn. The highest rates
are seen in individuals with repeated intense sun exposure.
This theory is further strengthened by the observation that pa-
tients with melanoma who actively reduce their sun exposure
after initial diagnosis are consequentlyat reduced risk of devel-
oping a second primary melanoma [20]. On the contrary, indi-
viduals with dark skin, or skin that darkens easily in response
to sunlight but does not burn, have demonstrably lower rates
of melanoma [17]. Patients with xeroderma pigmentosum
(XP) commonly develop cutaneous (and conjunctival) melano-
mas [21]; these individuals have a genetic inability to repair UV-
induced DNA damage, providing further support for the signif-
icance of UV radiation in melanomagenesis.
The age at which sun exposure and/or sunburn occurs also
appears to be important. Systematic review [19,22,23] has
strongly associated intermittent childhood or adolescent
sun exposure with a higher risk of melanoma. In particular,
individuals experiencing more than five episodes of severe
sunburn had a two-fold increased risk of melanoma [24,25].
Although the melanomagenic effects of UV-B exposure are
well evidenced, UV-A exposure is not without risk [26]. Long-
term follow-up of psoriasis patients has demonstrated that
those receiving UV-A therapy are at increased risk of develop-
ing melanoma [27]. Sunbeds emit UV-A radiation; a meta-
analysis of studies [28] exploring melanoma incidence follow-
ing sunbed use reported a 75% increase in risk in individuals
under 35 with a history of sunbed use. Further studies sup-
port this finding, drawing clear associations between mela-
noma risk and the amount of sunbed usage, particularly
from a young age [29–31]. The association was felt to be suffi-
ciently conclusive for UV light from sunbeds to be formally
classified as a human carcinogen [28,32]; unfortunately, de-
spite this evidence and consequent public health warnings,
sunbed tanning remains popular.
No other conclusive environmental risk factors – including
(unusually) smoking – have been identified. Smoking, a com-
mon carcinogen, has not been independently associated with
melanoma [33]. Interestingly, however, there is an association
between melanoma and comorbidities: for example, individu-
als who are immunosuppressed (due to organ transplanta-
tion) are at demonstrably higher risk of melanoma,
including recurrence in individuals with resected primary
melanomas prior to transplantation [34,35]. Also, patients
who have other skin malignancies (basal- or squamous-cellcarcinomas) are at higher risk of melanoma development
[36] and subsequent disease-related death [37].
It is also important to consider individual genetics when
determining personal risk. Clearly genetic factors such as
race and skin phenotype affect risk, as discussed earlier, but
it has also been estimated that approximately 10% of melano-
mas are familial in origin [38]. Some of these occur in specific
syndromes – such as familial atypical multiple mole and mel-
anoma syndrome (FAMMM) or dysplastic naevus syndrome
(DNS) – wherein individuals have multiple and phenotypically
variable moles at high risk of malignant transformation,
thereby presenting an almost guaranteed lifetime melanoma
risk. Many individuals will not meet the diagnostic criteria for
these syndromes but still have numerous naevi, often a
reflection of cumulative sun exposure. Observational studies
suggest a strong association between high naevus counts
and melanoma [39,40]. A personal history of cutaneous mela-
noma is also a known risk factor for further melanoma
primaries [41–43].
2.2. Biology
Aside from these familial syndromes, advances in gene anal-
ysis technology have allowed the investigation of less com-
mon but high-risk alleles that also appear to contribute to
cancer risk in individuals. Linkage studies focused on families
with a high incidence of melanomas [44–46] identified a mel-
anoma susceptibility locus on chromosome 9p21, subse-
quently found to represent the gene locus for CDKN2A
[47,48]. This gene locus undergoes complex transcription
(from alternate reading frames) and thus encodes two pro-
teins, p16 and p14ARF; the majority of mutations affect the
former protein [49,50].
p16 normally interacts with and inhibits cyclin-dependent
kinase 4 (CDK4). During the normal cell cycle, CDK4 com-
plexes with cyclin D, resulting in phosphorylation of the reti-
noblastoma (Rb1) protein, in turn releasing E2F-1 and thus
allowing it to induce S-phase gene synthesis; p16 therefore
acts as a negative regulator of the cell cycle [47,50]. Mutations
affecting this important protein disrupt its inhibitory func-
tion, thus deregulating the cell cycle. They are therefore
thought to prime melanocytes for malignancy. Evidence [51–
53] also exists for a pro-melanomagenic effect of germline
mutations affecting CDK4 and Rb1 directly. p14ARF also has
an important role in down-regulating p53 activity (through in-
creased activation of MDM2), thus also acting as a tumour
suppressor; disruption of this activity through mutations
could also be tumourigenic [54].
The actual prevalence of CDKN2A mutations is difficult to
quantify. In melanoma family studies estimates have ranged
from 20% to 57% [50], but in the general population are
thought to be considerably lower, in the region of 1.2–2.9%
[55]. Gene penetrance estimates are further complicated by
the knowledge that the environmental factors discussed ear-
lier further modulate risk in individuals with CDKN2A. Estab-
lishing the relative risk contribution from genes is therefore
more challenging. There may also be interaction between ge-
netic mutations to modulate melanoma risk further; for
example, some MC1R gene variants can increase the pene-
trance of CDKN2A mutations, thus increasing risk further
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nancies (e.g. pancreatic cancer) has also been demonstrated
[58–60].
BRCA2 is well associated with increased risk of breast
malignancies, but its role in melanoma is not fully estab-
lished. Given that some studies [61] suggest an increased risk
of melanoma in the presence of mutations in this gene,
whereas others [62] have been unable to demonstrate this,
no sound conclusions can be drawn regarding this gene.
Other genes are also being investigated; genome-wide associ-
ation studies [63–65] have identified several loci that may cor-
relate with increased melanoma risk, but the biological
mechanism of many of these has not yet been established.
Genetic mutations affecting protagonists of the mitogen-
activated protein kinase (MAPK) pathway have been found
in many tumour types. This key cell signalling pathway is
activated by ligand binding to a cell-surface receptor tyrosine
kinase (RTK), which in turn activates RAS. The RAS family of G
proteins consists of three isoforms, the most important of
which is NRAS. NRAS activation results in further pathway
signal transduction through phosphorylation (and conse-
quent activation) of the RAF proteins BRAF and CRAF [66].
Homo- or hetero-dimer formation of RAF molecules ulti-
mately leads to the activation of extracellular signal-regu-
lated kinase (ERK) which in turn acts on numerous targets
to promote cell growth and survival, as well as controlling fur-
ther MAPK pathway signalling by inducing the expression of
negative regulators [67], and directly inhibiting proteins such
as CRAF [68].
Mutations affecting this pathway are present in the vast
majority of cutaneous melanomas, predominantly affecting
the NRAS (approximately 20%) [69] or BRAF (approximately
40–50%) proteins [70]. In the case of BRAF, the vast majority
of mutations constitute a single amino acid substitution from
valine to glutamic acid at codon 600 (V600E), resulting in a
constitutively active BRAF protein that is consequently able
to signal in a continuous and unopposed fashion down the
MAPK pathway, thus promoting melanomagenesis and pre-
venting apoptosis [71,72]. Interestingly, a similar proportion
of naevi also contain BRAF mutations, implying that these
alone are not sufficient for malignant transformation [73].
It is hypothesised that whilst melanocyte acquisition of a
BRAF mutation is not the founder event for oncogenesis, it oc-
curs early in the development of invasive melanoma and fur-
ther enhances the effects of other oncogenic stimuli; thus it
facilitates malignant transformation, rather than initiating
it. BRAF mutations are more commonly seen in melanomas
arising in intermittently sun-exposed sites, implying that
UV light (as described earlier) may be one such stimulus.
Additionally, as there is significant interaction between intra-
cellular signalling pathways, further genetic aberrations
affecting the PI3 kinase pathway, for example, may also be
sufficient to induce melanoma development. Once developed,
however, there is clear tumour dependency on persistent acti-
vation of the MAPK pathway [72].
2.3. Prognosis
Prognostic factors in cutaneous melanoma have been closely
studied; they include histopathological characteristics, pa-tient characteristics, biochemical measures and most re-
cently genetic mutations. Each of these will be considered
in turn.
The American Joint Committee on Cancer (AJCC) staging
system [74] is globally acknowledged as an invaluable tool
in predicting outcomes for patients diagnosed with mela-
noma. It is based on data derived from analysis of tens of
thousands of cutaneous melanoma patients; the current sev-
enth edition was introduced early in 2010 and incorporated
new factors not previously used in the estimation of mela-
noma prognosis.
Histopathological features logically form the main criteria
for determining prognosis. Increasing thickness of the cuta-
neous primary correlates with worsening survival outcomes,
dropping from 96% 10-year survival for lesions <1 mm, to
54% for lesions >4 mm; even for lesions <1 mm in thickness,
there is further deterioration in outcome between lesions
<0.25 mm thickness and those >0.75 mm [75]. Moreover, at
each tumour thickness it has been demonstrated that the
presence of epithelial ulceration in the primary results in a
worse prognosis than if there is no ulceration [76,77]. These
two features (tumour thickness and ulceration) are arguably
the most powerful independent prognostic factors for cutane-
ous melanoma [76,78,79]. A third significant pathological fea-
ture is the mitotic rate [80,81]; a rate of >20 mitosis/mm2
results in a 10-year survival of approximately 48% relative to
93% in those individuals with <1 mitosis/mm2. Other features
of the primary associated with higher risk of relapse or
metastases are high tumour vascularity (i.e. new vessel for-
mation at the base of an invasive melanoma) [82,83] and lym-
phovascular invasion (tumour invasion of the dermis
microvasculature) [84]; the evidence for these factors is not
as conclusive as that for those discussed earlier.
The site of the primary also has important prognostic
implications; those arising centrally (trunk, head and neck)
tend to carry a worse prognosis than those arising on the
limbs (lower < upper) [76,85,86]. Additionally, cutaneous mel-
anoma can metastasise to lymph nodes. The presence of
lymph-node disease has adverse prognostic implications,
with further variation depending on the burden of nodal dis-
ease – both in terms of micrometastatic versus macroscopic
disease – and the number of lymph nodes involved. The pres-
ence of microscopic lymph-node disease results in 10-year
survival rates of 63%, but if macroscopic disease is present
this drops to 47% [76,87]. Similarly, there is a 10% 5-year sur-
vival deterioration with an increase in the number of nodes
involved (from 1 to 3) [87]; for those with macroscopic metas-
tases this increased risk is independent of other primary tu-
mour characteristics. Metastases to other sites have adverse
prognostic implications. Satellite cutaneous lesions reduce
survival by a similar proportion to lymph-node metastases
[88], with worsening prognosis with metastases to the lung
and further deterioration with any other organ involvement
[74,76].
In terms of patient characteristics, it is well established
that age is an independent prognostic factor, with worsening
outcome associated with increasing age [76,89,90]. Interest-
ingly, for early-stage (I–II) melanoma, female gender also
has positive prognostic implications [78,91–93], possibly re-
lated to the higher number of thin, non-ulcerated, extremity
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previously discussed are more prognostically significant than
gender.
With regard to biochemical features, serum lactate dehy-
drogenase (LDH) is well recognised as an independent prog-
nostic factor in cutaneous melanoma; in multivariate
analysis [74,94] a raised LDH level predicts approximately
50% lower survival rates in patients with distant metastases.
Other serum prognostic biomarkers have also been studied;
the most promising, S100 protein levels, correlate with sur-
vival in patients with resected locoregional disease [95,96],
with high levels predicting a significantly worse outcome
than with normal levels.
The increased use of gene expression profiling is also pro-
viding further genetic prognostic clues. The BRAF gene muta-
tion – which as previously described is integral to melanoma
pathogenesis – has been investigated as a prognostic marker
too. It appears to be linked to known prognostic factors such
as age and site of primary, whilst also being unrelated to fac-
tors such as site of metastasis and LDH [97]. In advanced dis-
ease, meta-analyses have demonstrated that the presence of
a BRAF mutation is independently associated with a worse
survival outcome [97–99]. The data in this area continue to
evolve.3. Uveal melanoma
Uveal melanoma is the most common primary ophthalmic
malignancy in adults and is associated with resistance to
available treatments and poor prognosis. The incidence of
uveal melanoma in Europe has been estimated as between
2 and 8 per million [100] and the median age at presentation
ranges from 55 to 60 years of age [101,102]. Both US [103] and
European [100] studies report that the incidence rate has been
stable since the 1970s, and disappointingly there has been no
improvement in survival over this time period. There is regio-
nal variation within Europe with an increase in incidence
from South to North, leading to the hypothesis that ocular
pigmentation may be protective [100]. Other incidence studies
support this hypothesis.
In the USA the majority of cases occur in the white popu-
lation [103]; there is a low incidence in South African black
populations [104] and in Far East Asian populations [105].
Case–control studies provide further supportive evidence that
lighter skin [106] and iris [107–109] colours are a risk factor for
the development of uveal melanoma. The role of UV-B radia-
tion in the pathogenesis of uveal melanoma is less clear as
studies rely on self-reported retrospective data on exposure
to sunlight. Some case–control studies have reported a weak
positive relationship between lifetime UV-B exposure and
uveal melanoma [106,110], whereas others have reported no
relationship [111,112]. Despite this the use of sunlamps is
recognised as a significant risk factor for the development
of uveal melanoma [106,109].3.1. Biology
Disruptions in a number of tumour suppressor genes and/or
activation of oncogenes have been implicated in the develop-ment of uveal melanoma. Disruption of the activity of the ret-
inoblastoma (Rb) tumour suppressor gene leads to
uninhibited progression of melanocytes through the G1–S
phase of the cell cycle, resulting in deregulated cell prolifera-
tion. Cyclin D4, either by over-expression [113] or lack of inhi-
bition by the tumour suppressor gene INK4a [114],
phosphorylates Rb resulting in its inactivation [113]. The p53
tumour suppressor gene is often functionally inhibited by
the over-expression of HDM2 resulting in the inhibition of
apoptosis [115]. Also PTEN, a negative regulator of the PI3K-
AKT pathway, is frequently inactivated or down-regulated in
uveal melanoma leading to increased cell proliferation and
survival [116].
More recently mutually exclusive mutations in GNAQ and
GNA11, genes encoding the alpha subunit of heterotrimeric
cell surface G proteins, have been reported. These alpha sub-
units are involved in mediating signals between G-protein-
coupled receptors and downstream effectors such as protein
kinases A and C [117]. Mutations in codon 209 of GNAQ and
GNA11 have been reported in approximately 46–49%
[118,119] and 32% [120] of patients, respectively, and lead to
constitutive activation of the G protein alpha subunit and
activation of the MAPK signalling pathway (in human mela-
nocyte cell lines), driving cell proliferation [118]. The majority
of substitutions at codon 209 of GNAQ and GNA11 involve
substitutions of glutamine by leucine or glutamine by proline
[118,120]. Mutations at codon 183 of GNAQ and GNA11 also
occur, although less frequently, and involve the substitution
of cytosine by thymine [118,120] which is characteristic of
ultraviolet-radiation-induced mutations [121], thereby sup-
porting the role of UV-B radiation in the pathogenesis of a
minority of uveal melanomas. As mutations in GNAQ and
GNA11 are common in uveal melanoma, targeting these or
downstream effectors such as protein kinase C [122] or mem-
bers of the MAPK signalling [123] pathway are promising po-
tential therapeutic options. However, the presence of these
mutations is not correlated with the development of meta-
static disease.
Inactivating somatic mutations of the gene coding for
BRCA1-associated protein-1 (BAP1) have been found in up to
85% of metastasising uveal melanomas [124]. BAP1 is a de-
ubiquitinating enzyme (DUB) encoded at the 3p21.1 locus
[125]. It regulates cell growth by mediating ubiquitination of
the nuclear transcription regulator, host cell factor 1 (HCFC1)
[126], and stabilises the BRCA1–BARD1 tumour suppressor
complex [127]. Also families with germ-line mutations of
BAP1 have been identified with an increased incidence of both
uveal and cutaneous melanoma, as well as other malignan-
cies [128–130].
Vascular endothelial growth factors (VEGFs) are a family of
five proteins which bind to VEGF receptors (VEGF-Rs) on endo-
thelial cells and promote angiogenesis. Increased VEGF
expression is involved in the pathogenesis of a number of so-
lid malignancies. The expression of VEGF is increased in hyp-
oxic environments [131], and raised VEGF-A levels have been
found in the aqueous humour of eyes with uveal melanoma
[132,133]. Significantly increased levels of VEGF-A have been
reported by some groups in patients with metastatic disease
[134], although not consistently [135]. The role of VEGF in
the pathogenesis of uveal melanoma requires further clarifi-
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melanoma, including uveal melanoma, are underway.
3.2. Prognosis
Major aberrations in karyotype are frequently observed in
uveal melanoma [136]. Monosomy 3 is the most common
and is reported in approximately 50% of cases treated with
enucleation [137]. It has been found to correlate with clinical
features of poor survival – such as large tumour size, tumours
of the ciliary body [138] and epithelioid cytology [139] – and is
also closely associated with the development of metastatic
disease [140]. Such patients with monosomy 3 uveal mela-
noma have a poor 5-year survival [141]. This may be due to
loss of tumour suppressor genes located on chromosome 3,
including BAP-1. It is likely that loss of chromosome 3 is an
early event in tumourigenesis, predisposing to other cytoge-
netic aberrations such as gain of 8q [142]. This is found in
around 40% of cases and corresponds to the locus for the
MYC proto-oncogene [143]. Together these cytogenetic abnor-
malities are more common in ciliary body tumours [144] and
are associated with the development of metastatic disease
[143]. Gain in chromosome 6p is associated with a better prog-
nosis. It has been observed in approximately 25% of tumours
and exclusively in tumours without monosomy 3 [143].
More recently gene expression profiling has identified two
distinct molecular subtypes (classes 1 and 2) of primary uveal
melanoma using a three-gene signature, with significant dif-
ferences in prognosis [145]. This signature identifies genes
which are involved in apoptosis, cell growth and angiogene-
sis. Class 1 tumours are associated with gain of chromosome
6 and are less likely to metastasise, whereas class 2 tumours
are associated with monosomy 3 and demonstrate a propen-
sity to metastasise. Consequently the 92-month survival for
class 1 and class 2 subtypes differed significantly at 95% and
31% respectively.4. Mucosal melanoma
Given that the primary function of melanocytes is pigmenta-
tion and protection of the skin and eyes against UV radiation,
their presence in unexposed sites such as mucous mem-
branes is not fully understood. There is accumulating evi-
dence that melanocytes function as antigen-presenting cells
[146,147], and as mucous membranes form a critical antimi-
crobial barrier, melanocytes at this site may have a role to
play as part of the innate immune system [148]. At leptome-
ningeal sites there is even evidence of a neuroendocrine role
[149]. Regardless of their function, mucosal membrane mela-
nocytes are susceptible to malignant transformation in a sim-
ilar fashion to their cutaneous and uveal counterparts.4.1. Epidemiology
Mucosal melanoma is the least common of the three mela-
noma subtypes, accounting for less than 1.5% of all melano-
mas [1,150]. The incidence rate is similar around the world
[151] and estimated at 2.2 [150] and 2.6 [152] cases per million
per year in the USA and Europe respectively. Significant regio-nal variation in incidence across Europe has been reported,
with the highest rate (2.7 cases per million per year) noted
in Northern Europe, and the lowest (0.88 cases per million
per year) in Eastern Europe [152], but this may simply reflect
differences in classification and reporting of this rare malig-
nancy. Interestingly, unlike cutaneous melanoma (which
demonstrates an annual increase in incidence), the annual
incidence of mucosal melanoma has remained relatively sta-
ble over several decades [1,150,153].
The incidence of mucosal melanoma varies with both gen-
der and age [150]. The median age at diagnosis is 70, with the
exception of oral cavity melanomas which tend to occur in
younger patients. Incidence increases with age; over 65% of
cases are diagnosed in patients over 60. The incidence in wo-
men is almost twice as high as in men, possibly because of
the higher rates of genital tract melanomas [1,154,155]
amongst women. The absolute incidence of mucosal mela-
noma in white populations is higher (2:1) than in non-whites
[1,150,155,156].
Mucosal melanomas arise most often in the head and neck
region, female genital tract and anorectal region [150]. No
clear risk factors for mucosal melanoma are known. As mu-
cous membranes are not exposed to the sun, UV radiation
is not considered an important aetiological factor. The role
of viruses – such as human papillomavirus (HPV) or human
herpes virus (HHV) implicated in other oral malignancies –
has not been substantiated [157–159]; however, a role for the
human immunodeficiency virus (HIV) has been postulated
[160,161] for anorectal mucosal melanomas. Inhaled chemical
irritants such as formaldehyde [162] are also not thought to be
significant carcinogens for this malignancy. It has been re-
ported that smoking is associated with a greater prevalence
of pigmented oral lesions [163]. Oral mucosal melanoma is
thought to be preceded by oral melanosis in one third of cases
[157,164,165], but no clear link to smoking has been identified,
particularly at other mucosal sites.
4.2. Biology
The advent of next-generation genomic sequencing has en-
abled detailed investigation of the molecular biology of this
rare melanoma subtype, and provided an insight into its
pathogenesis. Unlike cutaneous melanoma, V600E BRAF or
NRAS mutations are rare in mucosal melanoma [166,167]. In-
stead a distinct molecular mutation pattern exists, further
differentiating mucosal melanomas biologically from their
cutaneous and uveal counterparts.
The proto-oncogene, KIT, is a type III transmembrane
receptor tyrosine kinase (RTK) that dimerises upon extracel-
lular binding of its ligand stem-cell factor (SCF), activating
its intracellular tyrosine kinase domain and thus the receptor.
The activated protein, c-KIT, leads to phosphorylation of a
downstream intracellular signalling cascade and the activa-
tion of MAPK and phosphoinositide 3-kinase (PI3K) pathways
crucial for proliferation, migration, differentiation and sur-
vival in many cell types, including melanocytes [168,169].
Although the exact mechanism of KIT signalling in mela-
nocytes is not fully understood, studies have demonstrated
that inactivating mutations in KIT can lead to amelanotic dis-
orders [170,171] and prevent normal melanocyte development
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results in abnormal proliferation and melanocyte mobility
[173]. A loss/lack of KIT expression is often seen in progressive
melanoma [174,175]. Early studies on the genetic alterations
in mucosal melanoma led to the identification of chromo-
somal aberrations, such as gain of 1q, 6p and 8q [176–178].
Subsequently, detailed studies [179,180] comparing melano-
mas derived from different anatomical sites demonstrated
gain-of-function mutations (such as K642E, D816H and
V559A), amplifications or over-expression of c-KIT in 39% of
mucosal melanomas. This frequency is reported to vary
markedly by site of melanoma; in one study 88% of oral
mucosal melanomas were reported as expressing aberrant
c-KIT [181], while others [180] reported their highest rates
(35%) amongst genital tract melanomas. It was also noted
that mutations of KIT did not occur alongside mutations in
NRAS or BRAF [180].
Exon 11 mutations (including point mutations, in-frame
deletions and insertions) are the most common KIT muta-
tions; the L576P mutation in particular is found in approxi-
mately one third of these melanomas [166,179,180]. This
region encodes the juxtamembrane domain of the KIT recep-
tor, which performs an auto-inhibitory role. Mutations in this
region lead to constitutive receptor activation and consequent
abnormal intracellular growth signals, predominantly via the
PI3K pathway [182]. Experimental evidence suggests that such
activation alone is insufficient for mucosal melanoma gene-
sis, requiring further triggers within the cellular microenvi-
ronment (such as hypoxia) in order to induce malignant
transformation [182].
There is clearly still much to learn about the biology of
mucosal melanoma, but the knowledge gained thus far about
KIT mutations is encouraging further research in this area, fo-
cused particularly on exploiting this mutation in the pursuit
of effective treatment options for this condition. KIT muta-
tions have been successfully targeted in the treatment of
other malignancies such as gastrointestinal stromal tumours
(GIST), which also demonstrate an increased prevalence of
KIT mutations.
4.3. Prognosis
Mucosal melanoma has the poorest prognosis of all the mel-
anoma subtypes considered. Five-year survival estimates
range from 25% to 40% [1,152]. Interestingly, patients with
KIT mutations appear to have a poorer prognosis than wild-
type patients [183].
The site of these melanomas is often occult; early malig-
nant lesions are usually asymptomatic, and any subsequent
symptoms are non-specific, resulting in significant diagnostic
delay and enabling the lesion to grow and metastasise. Even
supposedly early-stage disease deemed to be fully surgically
resectable (and thus curable) often has a poor outcome. This
is most likely due to the presence of occult metastatic disease
at diagnosis. The lack of knowledge regarding disease risk
factors means that, in contrast with cutaneous melanoma,
strategies to improve mucosal melanoma outcomes must fo-
cus on early detection of the disease rather than avoidance of
risk factors and prevention of development.5. Conclusion
The socio-economic burden of melanoma is disproportionate
as its incidence is highest amongst younger, economically ac-
tive individuals. Both inherited, genetic and lifestyle factors
have been shown to affect the malignant transformation of
melanocytes. More recently it has become clear that cutane-
ous, mucosal and uveal melanomas are each distinct disease
entities with unique clinical behaviours and characteristic
molecular abnormalities. This improved understanding has
led to the development of new treatment strategies which
have started to improve outcomes. However, there is still a
long way to go as melanoma, for now, remains an assortment
of diseases with a common poor prognosis – particularly for
those with advanced disease.
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